Form 4: Orchestra BioMed Insider Tax Withholding Filing

Darren Sherman, President and COO of Orchestra BioMed, reported a routine tax-related share withholding transaction.

Summary

• Darren Sherman, President and COO of Orchestra BioMed Holdings, Inc., had 4,925 shares of common stock withheld by the company.
• The transaction occurred on May 28, 2026, at a price of $3.98 per share.
• The withholding was executed to satisfy tax obligations related to the vesting of restricted stock units (RSUs).
• Following this transaction, the reporting person maintains beneficial ownership of 1,199,327 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents a routine administrative tax obligation rather than a strategic or market-driven decision.

Positives

• The transaction was a non-discretionary tax withholding event rather than an open-market sale, indicating continued long-term holding by the executive.

Negatives

• None identified; this is a standard administrative procedure for equity compensation.

Risks

• None identified; this filing relates to internal tax compliance rather than operational or market risk.

Future Outlook

Not applicable as this is a retrospective disclosure of a completed transaction.

Management Comments

• The filing notes that no shares were sold in the market as a result of the vesting of these RSUs and the satisfaction of tax withholding obligations.

Industry Context

StockSavvy.ai notes that routine tax withholding filings are standard practice for executives in the biotechnology sector and do not typically signal changes in management sentiment or company outlook.

Comparison to Industry Standards

• The transaction follows standard corporate governance practices for equity-based compensation in the U.S. biotech industry.
• The use of net-settlement (withholding shares for taxes) is a common industry practice to avoid market volatility associated with sell-to-cover transactions.

Stakeholder Impact

• Minimal impact on shareholders as the transaction was a non-market tax settlement.

Next Steps

• None identified.

Key Dates

Keywords

Orchestra BioMed, OBIO, Form 4, Insider Trading, Tax Withholding, Equity Compensation